



# Screening KPI data summary factsheets November 2017 – Issue 1

Public Health England leads the NHS Screening Programmes

# About Public Health England

Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. We do this through world-leading science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health, and are a distinct delivery organisation with operational autonomy to advise and support government, local authorities and the NHS in a professionally independent manner. Public Health England, Wellington House, 133-155 Waterloo Road, London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE\_uk Facebook: www.facebook.com/PublicHealthEngland

## About PHE screening

Screening identifies apparently healthy people who may be at increased risk of a disease or condition, enabling earlier treatment or better informed decisions. National population screening programmes are implemented in the NHS on the advice of the UK National Screening Committee (UK NSC), which makes independent, evidence-based recommendations to ministers in the four UK countries. The Screening Quality Assurance Service ensures programmes are safe and effective by checking that national standards are met. PHE leads the NHS Screening Programmes and hosts the UK NSC secretariat.

PHE Screening, Floor 2, Zone B, Skipton House, 80 London Road, London SE1 6LH www.gov.uk/topic/population-screening-programmes Twitter: @PHE\_Screening Blog: phescreening.blog.gov.uk Prepared by: National Screening Data and Information Team For queries relating to this document, please contact: phe.screeninghelpdesk@nhs.net

#### © Crown copyright 2017

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL or email psi@nationalarchives.gsi.gov.uk. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published November 2017 PHE publications gateway number: 2017570



PHE supports the UN Sustainable Development Goals



# Introduction

This high-level report presents the key performance indicator (KPI) data for all 11 national screening programmes. The NHS Screening Programmes selected the KPIs to define consistent performance measures for a selection of public health priorities. The KPIs give a high level overview of the quality of screening programmes at key points on the screening pathway. They contribute to the quality assurance of screening programmes but are not, in themselves, sufficient to quality assure or performance manage screening services.

Screening KPIs are contained within the Section 7a agreements between the Department of Health (DH) and NHS England and in the Public Health Outcomes Framework (PHOF).

This report will focus on the most recent data collected with national comparisons to quarterly performance since 2014 to 2015 where available.

# **Further information**

This report should be read in conjunction with the full KPI dataset for Q1 2017 to 2018, and the KPI reporting data definitions for 2017 to 2018.

For all information about KPIs, including submission dates, templates and previous quarterly and annual data publications, please see our national data reporting page. Information about screening standards and service specifications are available for each programme.

Please contact the screening helpdesk if you would like further information on screening KPIs: phe.screeninghelpdesk@nhs.net.

# Index of KPIs Antenatal and newborn


KPI code	KPI name
<u>ID1</u>	Antenatal infectious disease screening – HIV coverage
<u>ID2</u>	Antenatal infectious disease screening – timely assessment of women with hepatitis B
<u>ID3</u>	Antenatal infectious disease screening – hepatitis B coverage
<u>ID4</u>	Antenatal infectious disease screening – syphilis coverage
<u>FA1</u>	Fetal anomaly screening – completion of laboratory request forms
<u>FA2</u>	Fetal anomaly screening – ultrasound coverage
<u>ST1</u>	Antenatal sickle cell and thalassaemia screening – coverage
<u>ST2</u>	Antenatal sickle cell and thalassaemia screening – timeliness of test
<u>ST3</u>	Antenatal sickle cell and thalassaemia screening – completion of FOQ
<u>NB1</u>	Newborn blood spot screening - coverage (CCG responsibility at birth)
<u>NB2</u>	Newborn blood spot screening – avoidable repeat tests
<u>NB4</u>	Newborn blood spot screening – coverage (movers in)
<u>NH1</u>	Newborn hearing screening – coverage
<u>NH2</u>	Newborn hearing – time from screening outcome to attendance at an audiological assessment appointment
<u>NP1</u>	Newborn and infant physical examination – coverage (newborn)
<u>NP2</u>	Newborn and infant physical examination – timely assessment of developmental dysplasia of the hip (DDH)

# Index of KPIs

# Young person and adult

KPI code	KPI name
<u>DE1</u>	Diabetic eye screening – uptake of routine digital screening event
<u>DE2</u>	Diabetic eye screening - results issued within 3 weeks of routine digital screening
<u>DE3</u>	Diabetic eye screening – timely assessment for R3A screen positive
<u>AA2</u>	Abdominal aortic aneurysm screening – coverage of initial screen
<u>AA3</u>	Abdominal aortic aneurysm screening – coverage of annual surveillance screen
<u>AA4</u>	Abdominal aortic aneurysm screening – coverage of quarterly surveillance screen
BCS1	Bowel cancer screening – uptake
BCS2	Bowel cancer screening – coverage
<u>BS1</u>	Breast screening – uptake
<u>BS2</u>	Breast screening – screening round length
<u>CS1</u>	Cervical screening – coverage (under 50)
<u>CS2</u>	Cervical screening – coverage (50 and above)


## Infectious diseases in pregnancy (IDPS) programme KPI ID1: HIV coverage



National trend data




\*Thresholds changed in 2016 to 2017





#### **KPI ID1 description**

The proportion of pregnant women eligible for HIV screening for whom a confirmed screening result is available at the day of report

## Infectious diseases in pregnancy (IDPS) programme KPI ID2: Timely assessment of women with hepatitis B







#### **KPI ID2 description**

The proportion of pregnant women who are hepatitis B positive attending for specialist assessment within 6 weeks of the positive result being reported to maternity services

## Infectious diseases in pregnancy (IDPS) programme KPI ID3: Hepatitis B coverage



ID3 is a new KPI introduced in 2017 to 2018. As a new KPI in the first year of collection, ID3 is used by healthcare professionals and quality assurance services as an experimental indicator. In this period we will aim to improve the data quality and completeness with the planned formal publication from 2018 to 2019

#### **KPI ID3 description**

The proportion of pregnant women eligible for hepatitis B screening for whom a confirmed screening result is available at the day of report

# Infectious diseases in pregnancy (IDPS) programme

## KPI ID4: Syphilis coverage





ID4 is a new KPI introduced in 2017 to 2018. As a new KPI in the first year of collection, ID4 is used by healthcare professionals and quality assurance services as an experimental indicator. In this period we will aim to improve the data quality and completeness with the planned formal publication from 2018 to 2019


#### **KPI ID4 description**

The proportion of pregnant women eligible for syphilis screening for whom a confirmed screening result is available at the day of report

## Fetal anomaly screening programme (FASP) KPI FA1: Completion of laboratory request forms







#### **KPI FA1 description**


The proportion of laboratory request forms including complete data prior to screening analysis, submitted to the laboratory within the recommended timeframe of 10<sup>+0</sup> to 20<sup>+0</sup> weeks' gestation

## Fetal anomaly screening programme (FASP) **KPI FA2: Ultrasound coverage**



FA2 was introduced in 2016 to 2017. During the first year of collection FA2 was used by healthcare professionals and quality assurance services as an experimental indicator. Publication of FA2 begins in 2017 to 2018; as FA2 is available 6 months in arrears it will be published in future issues of this report.

National trend data



- performance =
- Completeness of data:

#### **KPI FA2 description**

20

0

England

Midlands

& East


London

North


South

The proportion of pregnant women eligible for fetal anomaly ultrasound screening who are tested leading to a conclusive result within the designated timescale

## Sickle cell and thalassaemia (SCT) screening programme KPI ST1: Coverage




National trend data




#### **KPI ST1 description**

The proportion of pregnant women eligible for antenatal sickle cell and thalassaemia screening for whom a screening result is available at the day of report

## Sickle cell and thalassaemia (SCT) screening programme KPI ST2: Timeliness of test









#### **KPI ST2 description**


The proportion of women having antenatal sickle cell and thalassaemia screening for whom a screening result is available by 10 weeks + 0 days gestation

## Sickle cell and thalassaemia (SCT) screening programme KPI ST3: Completion of FOQ



National trend data







#### **KPI ST3 description**

The proportion of antenatal sickle cell and thalassaemia samples submitted to the laboratory accompanied by a completed FOQ


## Newborn blood spot (NBS) screening programme KPI NB1: Coverage (CCG responsibility at birth)



National trend data



\*Achieveable threshold changed in 2017 to 2018





#### **KPI NB1 description**

The proportion of babies registered within the clinical commissioning group (CCG) both at birth and on the last day of the reporting period who are eligible for newborn blood spot (NBS) screening and have a conclusive result recorded on the child health information system (CHIS) at less than or equal to 17 days of age


Reported by: CCG

## Newborn blood spot (NBS) screening programme KPI NB2: Avoidable repeat tests





\*Achievable threshold changed in 2017 to 2018




#### **KPI NB2 description**


The proportion of first blood spot samples that require repeating due to an avoidable failure in the sampling process

## Newborn blood spot (NBS) screening programme KPI NB4: Coverage (movers in)





\*Achievable threshold changed in 2017 to 2018





#### **KPI NB4 description**


The proportion of all babies eligible for newborn blood spot (NBS) screening who have changed responsible CCG in the first year of life; or have moved in from another UK country or abroad, and have a conclusive result recorded on the CHIS at less than or equal to 21 calendar days of notifying the CHRD of movement in

Reported by: CCG


## Newborn hearing screening programme (NHSP) KPI NH1: Coverage







\*Threshold changed in 2016 to 2017




#### **KPI NH1 description**


The proportion of babies eligible for newborn hearing screening for whom the screening process is complete by 4 weeks corrected age (hospital programmes: well babies, NICU babies) or by 5 weeks corrected age (community programmes: well babies) Reported by: Local NHSP site


Back to index

## Newborn hearing screening programme (NHSP)

# KPI NH2: Time from screening outcome to attendance at an audiological assessment appointment








#### **KPI NH2 description**

The proportion of babies with a no clear response result in one or both ears or other result that require an immediate onward referral for audiological assessment who receive audiological assessment within the required timescale

Reported by: Local NHSP site

# Newborn and infant physical examination (NIPE) screening programme

## KPI NP1: Coverage (newborn)




#### **KPI NP1 description**


The proportion of babies eligible for the newborn physical examination who are tested for all 4 components (3 components in female infants) of the newborn examination within 72 hours of birth

# Newborn and infant physical examination (NIPE) screening programme

# KPI NP2: Timely assessment of developmental dysplasia of the hip








#### **KPI NP2 description**


The proportion of babies who have a positive screening test on newborn physical examination and undergo assessment by specialist hip ultrasound within 2 weeks of age

## Diabetic eye screening (DES) programme KPI DE1: Uptake of routine digital screening event





\*Thresholds changed in 2017 to 2018




#### **KPI DE1 description**


The proportion of those offered routine digital screening who attend a digital screening event where images are captured

Reported by: Local DES service

### Diabetic eye screening (DES) programme

### KPI DE2: Results issued within 3 weeks of routine digital screening, digital surveillance or slit lamp biomicroscopy





Reporting period: Q1 2017 to 2018 England

- numerator =
- denominator =
- performance =

Completeness of data:

## **KPI DE2 description**

60

40

20

0

England

London

Midlands

& East

North


South

The proportion of subjects attending for diabetic eye screening, digital surveillance or slit lamp biomicroscopy to whom results were issued within 3 weeks of the screening event

Reported by: Local DES service

## Diabetic eye screening (DES) programme

### KPI DE3: Timely assessment for R3A screen positive



#### **KPI DE3 description**

The proportion of screen positive subjects with referred proliferative (R3A) diabetic retinopathy attending for assessment within 6 weeks of their screening event from all diabetic eye screening pathways

Reported by: Local DES service

## Abdominal aortic aneurysm (AAA) screening programme


### KPI AA2: Coverage of initial screen




2016 to 2017 was the first year of data publication for AA2. AA2 is an annual indicator, quarterly figures are aggregated from Q1 to the current quarter

The performance thresholds for AA2 increase on a quarterly basis in order to best reflect the nature of the local screening service call to screening

National performance of AA2 in Q1 was above the achievable threshold. 33 out of 41 screening providers met the acceptable threshold of 18%






#### **KPI AA2 description**


The proportion of men eligible for abdominal aortic aneurysm screening who are conclusively tested

Reported by: Local AAA screening service

# Abdominal aortic aneurysm (AAA) screening programme KPI AA3: Coverage of annual surveillance screen



National trend data



performance = 90.9%

Completeness of data: 100%

#### **KPI AA3 description**

0

England

London

Midlands

& East

North

South


The proportion of annual surveillance appointments due where there is a conclusive test within 6 weeks of the due date

Reported by: Local AAA screening service

# Abdominal aortic aneurysm (AAA) screening programme KPI AA4: Coverage of quarterly surveillance screen








#### **KPI AA4 description**

The proportion of quarterly surveillance appointments due where there is a conclusive test within 4 weeks of the due date


Reported by: Local AAA screening service


# Bowel cancer screening programme (BCSP)

## KPI BCS1: Uptake



#### National trend data





#### **KPI BCS1 description**

The proportion of eligible men and women aged 60 to 74 years invited to participate in bowel cancer screening who adequately participate

Reported by: Local screening centre (also by CCG in the data publication)


# Bowel cancer screening programme (BCSP)

## KPI BCS2: Coverage



#### National trend data







#### **KPI BCS2 description**


The proportion of eligible men and women aged 60 to 74 years invited for screening who have had an adequate FOBt screening result in the previous 30 months

Reported by: Local authority

## Breast screening programme (BSP) KPI BS1: Uptake









#### KPI BS1 description


The proportion of eligible women invited who attend for screening

Reported by: Local screening service

## Breast screening programme (BSP) KPI BS2: Screening round length









#### **KPI BS2 description**

The proportion of eligible women whose date of first offered appointment is within 36 months of their previous screen. Women being screened for the first time will not be included in screening round length statistics

Reported by: Local screening service

# Cervical screening programme (CSP) KPI CS1: Coverage (under 50 years)





#### **KPI CS1 description**

The proportion of women in the resident population eligible for cervical screening aged 25 to 49 years at end of period reported who were screened adequately within the previous 3.5

Reported by: CCG

40

20

0

Q1

Q2

2014 to 2015

Q3

Q4

Q1

Q2

2015 to 2016

Q3

Q4

Q1

Q2

2016 to 2017

Q3

Q4

Q1

Q2


2017 to 2018

Q3

Q4

years

## Cervical screening programme (CSP) KPI CS2: Coverage (50 years and above)



#### **KPI CS2 description**

The proportion of women in the resident population eligible for cervical screening aged 50 to 64 years at end of reported period who were screened adequately within the previous 5.5 years Reported by: CCG